Concepedia

Marc Damelin

MD

Statistics

Publications

27

Citations

1.8K

H-Index

21

Active since

1999

Affiliations

Mersana Therapeutics (United States)(Current)

Pfizer (United States)

Harvard University

Dana-Farber Cancer Institute

Columbia University

Marc Damelin is an author at Mersana Therapeutics (United States) specializing in oncology, antibody-drug conjugate therapy, and antibody-drug conjugates.

ORCID

Publications per year

1999–2025

27

Publications

27

Hyperconserved CpG domains underlie Polycomb-binding sites

Amos Tanay, Anne O’Donnell‐Luria, Marc Damelin et al. · Proceedings of the National Academy of Sciences · 2007 · 176 citations · Full text

, , +17

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Marc Damelin, Alexander J. Bankovich, Jeffrey Bernstein et al. · Science Translational Medicine · 2017 · 157 citations

, , +16

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

Marc Damelin, Wenyan Zhong, Jeremy S. Myers et al. · Pharmaceutical Research · 2015 · 151 citations

, , +14

The Genome-Wide Localization of Rsc9, a Component of the RSC Chromatin-Remodeling Complex, Changes in Response to Stress

Marc Damelin, Itamar Simon, Terence I. Moy et al. · Molecular Cell · 2002 · 146 citations · Full text

, , +14

Mapping Interactions between Nuclear Transport Factors in Living Cells Reveals Pathways through the Nuclear Pore Complex

Marc Damelin, Pamela A. Silver · Molecular Cell · 2000 · 138 citations · Full text

, , +16

1–5 of 27